Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6694497 | 0.69 | MEN1 (0.36) | DPP4MEN1KMT2A | |
| SCHEMBL6697812 | 0.60 | CYP2C9 (0.33) | — | |
| SCHEMBL6696196 | 0.59 | MAOA (0.40) | OPRD1MEN1KMT2A | |
| SCHEMBL12533132 | 0.59 | MAPK1 (0.47) | DPP4MEN1KMT2A | |
| SCHEMBL8181127 | 0.58 | KMT2A (0.46) | TSHRMEN1KMT2A | |
| SCHEMBL31332341 | 0.53 | SIGMAR1 (0.54) | TSHRMEN1KMT2A | |
| SCHEMBL2849413 | 0.52 | MAOA (0.53) | TSHR | |
| SCHEMBL10280392 | 0.52 | MAPK1 (0.47) | — | |
| SCHEMBL2818152 | 0.51 | MAPK1 (0.63) | DPP4MEN1KMT2A | |
| SCHEMBL15919668 | 0.51 | NPY2R (0.81) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040009972-A1 | Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase | BRISTOL-MYERS COMPANY | 2004-01-15 | — | — | US | disclosed |
| WO-2003106628-A2 | BENZODIAZEPINE INHIBITORS OF MITOCHONDIAL F1F0 ATP HYDROLASE AND METHODS OF INHIBITING F1F0 ATP HYDROLASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009972-A1 | Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase | MT-ATP6, MT-CO1, ATP5ME | TSHR 1979/4885OPRD1 289/4885DPP4 3992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.